Contact us
Expertise in real world data
Why Oxon
OXON's record of being associated with top quality publications provides clients with the reassurance that they will receive scientific rigour in the design, analysis, interpretation of their studies as well as high quality reports and manuscripts:
· The Lancet

N Qizilbash, J Gregson, ME Johnson, N Pearce, I Douglas, K Wing, SJW Evans, SJ Pocock. 2015. BMI and risk of dementia in two million people over two decades: a retrospective cohort study. The Lancet Diabetes and Endocrinology, 3(6): 431 – 436.

G Whitlock, S Lewington, P Sherliker, R Clarke, J Emberson, J Halsey, N Qizilbash, R Collins, and R Peto. 2009. “Body-Mass Index and Cause-Specific Mortality in 900 000 Adults: Collaborative Analyses of 57 Prospective Studies.” The Lancet 373(9669): 1083–96.

S Lewington, G Whitlock, R Clarke, P Sherliker, J Emberson, J Halsey, N Qizilbash, R Peto, and R Collins. 2007. “Blood Cholesterol and Vascular Mortality by Age, Sex, and Blood Pressure: A Meta-Analysis of Individual Data from 61 Prospective Studies with 55,000 Vascular Deaths.” The Lancet 370(9602): 1829–39.

S Lewington, R Clarke, N Qizilbash, R Peto, and R Collins. 2002. “Age-Specific Relevance of Usual Blood Pressure to Vascular Mortality: A Meta-Analysis of Individual Data for One Million Adults in 61 Prospective Studies.” The Lancet 360(9349): 1903–13.

Prospective Studies Collaboration. 1995. “Cholesterol, Diastolic Blood Pressure, and Stroke: 13 000 Strokes in 450 000 People in 45 Prospective Cohorts.” The Lancet 346(8991-8992): 1647–53.

JM Giné, A Maguire, and O Ramis-Juan. 1991. “Fatal Road Accidents in Catalonia.” The Lancet 338: 122–23.

R Collins, R Peto, S MacMahon, P Hebert, NH Fiebach, KA Eberlein, J Godwin, N Qizilbash, JO Taylor, and CH Hennekens. 1990. “Blood Pressure, Stroke, and Coronary Heart Disease. Part 2, Short-Term Reductions in Blood Pressure: Overview of Randomised Drug Trials in Their Epidemiological Context.” The Lancet 335(8693): 827–38.


N Qizilbash, L Jones, C Warlow, and J Mann. 1991. “Fibrinogen and Lipid Concentrations as Risk Factors for Transient Ischaemic Attacks and Minor Ischaemic Strokes.” BMJ 303(6803): 605–9.

Antiplatelet Trialists’ Collaboration. 1994. “Collaborative Overview of Randomised Trials of Antiplatelet Therapy--I: Prevention of Death, Myocardial Infarction, and Stroke by Prolonged Antiplatelet Therapy in Various Categories of Patients.” BMJ 308(6921): 81–106.

Antiplatelet Trialists’ Collaboration. 1988. “Secondary Prevention of Vascular Disease by Prolonged Antiplatelet Treatment. Antiplatelet Trialists’ Collaboration.” BMJ 296(6618): 320–31.


N Qizilbash, A Whitehead, J Higgins, G Wilcock, L Schneider, and M Farlow. 1998. “Cholinesterase Inhibition for Alzheimer Disease: A Meta-Analysis of the Tacrine Trials. Dementia Trialists’ Collaboration.” JAMA 280(20): 1777–82.

· Circulation

LA García Rodríguez, C Varas-Lorenzo, A Maguire, and A González-Pérez. 2004. “Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population.” Circulation 109(24): 3000–3006.

< 12 >
Copyright © 2013 Oxon All Rights Reserved - Late phase CRO